1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
iNtRON Biotechnology, Inc.

iNtRON Biotechnology, Inc.

KKRX:048530
3,065.00
KRW
-90.00
(-2.85%)
-288.21EPS
126.04BMarket Cap
Nov 12Next Earn
iNtRON Biotechnology, Inc.
KRX:048530
(Korea Stock Exchange)

Recent

price

3,065.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
341.29
362.19
347.8
340.98
357.53
406.43
340.46
365.88
343.84
277.62
1,382.94
867.67
411.98
288.69
195.67
181.3
201.91
Revenue per Share
28.46
13.71
-50.39
13
0.74
53.5
-75
-291.5
145.5
-106
455
288
168
-292
-79
-282.94
-288.21
Basic EPS, GAAP
42.42
-109.78
-129.1
-91.66
-43.71
-157.98
-222.7
-223.72
57.91
-49.4
32.28
384.23
98.83
-193.78
-40.39
-242.52
-361.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
101.2
101
- -
Dividend per Share
342.36
427.1
492.29
625.83
695.71
1,147.79
1,283.15
1,003.02
1,298.48
2,136.62
2,595.08
3,004.79
3,199.04
2,914.42
2,619.7
2,261.88
2,085.58
Book Value per Share
160.73
211.54
218.14
352.17
391.37
815.68
1,259.37
973.62
1,266.71
2,097.16
2,560.55
2,968.84
3,157.3
2,872.08
2,576.77
2,228.23
2,052.88
Tangible Book Value per Share
23
24
24
27
28
29
30
30
60
30
33
34
34
33
33
32
32
Basic Weighted Avg Shares
7,703
8,553
8,174
9,277
9,980
11,835
10,222
10,963
20,584
8,347
45,433
29,308
14,007
9,585
6,418
5,740
6,437
Sales/Revenue/Turnover
11.41
3.49
-13.64
0.63
11.27
18.01
-33
-35.58
25.1
-52.33
34.64
34.38
-10.56
-34.27
-81.61
-137.69
-127.86
Operating Margin (%)
610
749
1,005
1,035
811
972
744
896
940
1,424
1,569
1,536
1,567
1,912
2,026
1,946
1,918
Depreciation Expense
642
324
-1,184
354
21
1,558
-2,252
-8,734
8,711
-3,187
14,948
9,728
5,712
-9,695
-2,591
-8,958
-9,188
Net Income, GAAP
- -
- -
- -
- -
- -
0.24
- -
- -
- -
- -
12.33
8.01
31.34
- -
- -
- -
- -
Effective Tax Rate (%)
8.34
3.79
-14.49
3.81
0.21
13.16
-22.03
-79.67
42.32
-38.18
32.9
33.19
40.78
-101.15
-40.37
-156.06
-142.74
Profit Margin (%)
2,703
7,016
4,079
5,849
19,845
15,989
26,651
17,279
25,988
70,611
68,623
92,259
81,710
60,194
50,888
39,729
36,649
Working Capital
1,858
5,914
2,732
396
13,152
1,747
1,548
552
225
14,090
174
16,128
286
258
1,076
220
1,975
LT Debt
7,712
10,004
11,929
17,484
19,389
34,442
38,633
30,298
39,146
65,019
85,379
101,349
106,181
96,734
83,773
69,873
64,427
Total Equity
- -
- -
- -
- -
- -
6.09
- -
- -
- -
- -
15.78
8.53
-0.82
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
5.73
- -
- -
- -
- -
18.19
10.32
6.53
- -
- -
- -
- -
Return on Capital (%)
8.69
3.66
-10.8
2.4
0.11
5.79
-6.18
-25.52
25.28
-6.2
20.03
10.43
5.5
-9.56
-2.87
-11.66
-13.01
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3,139
3,134
3,109
LT Borrowings
- -
- -
1,800
LT Finance Leases
127
220
175
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
31
31
Market Capitalization
118,236
100,398
126,038

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
47,102
43,815
40,809
Cash, Cash Equivalents & STI
38,194
41,775
36,621
Accounts Receivable, Net
- -
817
1,659
Inventories
913
842
816
Total Current Liabilities
4,402
4,086
4,160
Payables & Accruals
- -
- -
- -
ST Debt
3,139
3,134
3,109
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.18%
-3.08%
-16.59%
Free Cash Flow
73.79%
231.66%
479.59%
Net Income, GAAP
-103.55%
-34.7%
245.73%
Sales/Revenue/Turnover
30.33%
-32.58%
-10.56%
Total Cash Common Dividend
- -
- -
-3.66%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,910
1,778
1,208
1,522
6,418
2025
1,186
1,226
1,623
1,704
5,740
2026
1,883
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-12
17
-40
-45.08
-79
2025
-59.85
-32.72
-52.59
-135.28
-282.94
2026
-72.53
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
105.98
- -
- -
- -
101.2
2025
94.11
- -
- -
- -
101
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
iNtRON Biotechnology, Inc. (048530.KQ) develops innovative biopharmaceuticals, diagnostic kits and reagents in South Korea. The company offers bacteriophage- and endolysin-based therapeutics such as SAL200 for superbug treatment including MRSA; itLysin platform drugs; PHAGERIA and PHAGERIARUS technologies targeting antibiotic alternatives for humans and animals; molecular diagnostics under the LiliF brand encompassing MDx PCR kits for high specificity drug resistance, gastric fever and tropical diseases, RDT rapid screening tests, and life science reagents from nucleic acid extraction to detection; as well as antibiotic alternatives for livestock and research products like mycoplasma detection kits and LPS extraction solutions. Founded in 1999 and headquartered in Seongnam-si, Gyeonggi-do, the company operates primarily in South Korea with global R&D ambitions, ISO9001, ISO13485 and GMP-certified production, and over 400 patents in phage and endolysin technologies. Recent developments include successful preclinical validation of IMPA platform enhancements with Mini-Hoc for GLP-1 targeted phages and modular phages like Tg-Phage P against Pasteurella; in vivo efficacy of TgC-Phage E reducing pks+ E. coli in colorectal cancer models; and PoC results for SAL200-based nasal decolonization agent INT-214 demonstrating MRSA clearance in animal studies for surgical site infection prevention, prompting 2025 clinical plans and partner searches.